Your browser doesn't support javascript.
Combination treatments with hydroxychloroquine and azithromycin are compatible with the therapeutic induction of anticancer immune responses.
Liu, Peng; Zhao, Liwei; Ferrere, Gladys; Alves-Costa-Silva, Carolina; Ly, Pierre; Wu, Qi; Tian, Ai-Ling; Derosa, Lisa; Zitvogel, Laurence; Kepp, Oliver; Kroemer, Guido.
  • Liu P; Equipe labellisée par la Ligue contre le cancer, Université de Paris, Sorbonne Université, INSERM UMR1138, Centre de Recherche DES Cordeliers, Paris, France.
  • Zhao L; Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France.
  • Ferrere G; Equipe labellisée par la Ligue contre le cancer, Université de Paris, Sorbonne Université, INSERM UMR1138, Centre de Recherche DES Cordeliers, Paris, France.
  • Alves-Costa-Silva C; Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France.
  • Ly P; Inserm U1015, Gustave Roussy Cancer Campus, Villejuif, France.
  • Wu Q; Université Paris-Saclay, Saint-Aubin, France.
  • Tian AL; Inserm U1015, Gustave Roussy Cancer Campus, Villejuif, France.
  • Derosa L; Université Paris-Saclay, Saint-Aubin, France.
  • Zitvogel L; Inserm U1015, Gustave Roussy Cancer Campus, Villejuif, France.
  • Kepp O; Université Paris-Saclay, Saint-Aubin, France.
  • Kroemer G; Equipe labellisée par la Ligue contre le cancer, Université de Paris, Sorbonne Université, INSERM UMR1138, Centre de Recherche DES Cordeliers, Paris, France.
Oncoimmunology ; 9(1): 1789284, 2020 07 08.
Article in English | MEDLINE | ID: covidwho-1066080
ABSTRACT
Amid controversial reports that COVID-19 can be treated with a combination of the antimalarial drug hydroxychloroquine (HCQ) and the antibiotic azithromycin (AZI), a clinical trial (ONCOCOVID, NCT04341207) was launched at Gustave Roussy Cancer Campus to investigate the utility of this combination therapy in cancer patients. In this preclinical study, we investigated whether the combination of HCQ+AZI would be compatible with the therapeutic induction of anticancer immune responses. For this, we used doses of HCQ and AZI that affect whole-body physiology (as indicated by a partial blockade in cardiac and hepatic autophagic flux for HCQ and a reduction in body weight for AZI), showing that their combined administration did not interfere with tumor growth control induced by the immunogenic cell death inducer oxaliplatin. Moreover, the HCQ+AZI combination did not affect the capacity of a curative regimen (cisplatin + crizotinib + PD-1 blockade) to eradicate established orthotopic lung cancers in mice. In conclusion, it appears that HCQ+AZI does not interfere with the therapeutic induction of therapeutic anticancer immune responses.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Azithromycin / COVID-19 Drug Treatment / Hydroxychloroquine / Neoplasms Type of study: Prognostic study / Randomized controlled trials Topics: Traditional medicine Limits: Animals / Female / Humans Country/Region as subject: Europa Language: English Journal: Oncoimmunology Year: 2020 Document Type: Article Affiliation country: 2162402X.2020.1789284

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Azithromycin / COVID-19 Drug Treatment / Hydroxychloroquine / Neoplasms Type of study: Prognostic study / Randomized controlled trials Topics: Traditional medicine Limits: Animals / Female / Humans Country/Region as subject: Europa Language: English Journal: Oncoimmunology Year: 2020 Document Type: Article Affiliation country: 2162402X.2020.1789284